0001209191-17-018771.txt : 20170307
0001209191-17-018771.hdr.sgml : 20170307
20170307164706
ACCESSION NUMBER: 0001209191-17-018771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170303
FILED AS OF DATE: 20170307
DATE AS OF CHANGE: 20170307
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: JUNIPER PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000821995
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 592758596
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-639-1500
MAIL ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
FORMER COMPANY:
FORMER CONFORMED NAME: COLUMBIA LABORATORIES INC
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Secor Alicia
CENTRAL INDEX KEY: 0001584516
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10352
FILM NUMBER: 17672578
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-03-03
0
0000821995
JUNIPER PHARMACEUTICALS INC
JNP
0001584516
Secor Alicia
C/O JUNIPER PHARMACEUTICALS INC.
33 ARCH STREET, SUITE 3110
BOSTON
MA
02110
1
1
0
0
President and CEO
Common Stock
2017-03-03
4
A
0
26200
0.00
A
31200
D
Employee Stock Option (Right to Buy)
5.15
2017-03-03
4
A
0
127500
0.00
A
2024-03-03
Common Stock, $0.01 par value per share
127500
127500
D
This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years.
The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant.
/s/ Jeffrey Young, Attorney-in-Fact
2017-03-07
EX-24.4_710123
2
poa.txt
POA DOCUMENT
Power of Attorney
Know all by these presents that the undersigned hereby constitutes and
appoints each of Alicia Secor and Jeffrey Young, and with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or a director of Juniper Pharmaceuticals, Inc., a Delaware
corporation (the Company), Forms 3, 4, and 5 in accordance with Section 16(a) of
the Securities Exchange Act of 1934, as amended, and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the SEC and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 3rd day of March, 2017.
/s/ Alicia Secor
Name: Alicia Secor